Study on the mechanism of pirfenidone in the treatment of connective tissue disease with interstitial lung disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100046283

Enrollment

Unknown

Registered

2021-05-12

Start date

2021-05-30

Completion date

Unknown

Last updated

2021-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

Experimental group:pirfenidone

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 70 years (including 18 and 70 years) ; 2. Clinically diagnosed connective tissue disease with Interstitial lung disease disease (confirmed by HRCT) .

Exclusion criteria

Exclusion criteria: 1. Patients who are allergic to pirfenidone capsules; 2. Patients whose symptoms of dyspnea have alleviated in the past six months; 3. Patients with emphysema, asthma, tuberculosis, sarcoidosis, bronchiectasis, or infection; 4. Diabetics with poor blood sugar control; 5. Combined with malignant tumor, severe liver, kidney or heart disease; 6. Pregnant and lactating women; 7. Patients with mental illness; 8. Participants in clinical trials of other drugs within 3 months.

Design outcomes

Primary

Measure	Time frame
cytokine;	—

Countries

China

Contacts

Public ContactZhang Hongfeng

The First Affiliated Hospital of Dalian Medical University

zhanghongfeng09@sina.com+86 18098877917

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026